2. Academic Validation
  3. Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

  • RSC Med Chem. 2020 Apr 6;11(4):455-490. doi: 10.1039/d0md00062k.
Godwin Akpeko Dziwornu 1,  Henrietta Dede Attram 1,  Samuel Gachuhi 1,  Kelly Chibale 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Chemistry , University of Cape Town , Rondebosch 7701 , South Africa . Email: kelly.chibale@uct.ac.za ; Tel: +27 21 6502553.
  • 2 Drug Discovery and Development Centre (H3D) , University of Cape Town , Rondebosch 7701 , South Africa.
  • 3 Institute of Infectious Disease and Molecular Medicine , University of Cape Town , Rondebosch 7701 , South Africa.
  • 4 South African Medical Research Council Drug Discovery and Development Research Unit , University of Cape Town , Rondebosch 7701 , South Africa.
PMID: 33479649 DOI: 10.1039/d0md00062k
Abstract

Globally, schistosomiasis threatens more than 700 million lives, mostly children, in poor localities of tropical and sub-tropical areas with morbidity due to acute and chronic pathological manifestations of the disease. After a century since the first antimonial-based drugs were introduced to treat the disease, anti-schistosomiasis drug development is again at a bottleneck with only one drug, praziquantel, available for treatment purposes. This review focuses on promising chemotypes as potential starting points in a drug discovery effort to meet the urgent need for new schistosomicides.

Figures